Edwards Lifesciences Corporation Revenue
Edwards Lifesciences Corporation (EW) reported Revenue of $1.74 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.74B, a 13.63% increase year-over-year.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.65B, a 16.70% increase year-over-year.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.57B, a 13.26% increase year-over-year.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.55B, a 14.67% increase year-over-year.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for fiscal 2025 was $6.07B, a 11.55% increase from fiscal 2024.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for fiscal 2024 was $5.44B, a 8.57% increase from fiscal 2023.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for fiscal 2023 was $5.01B, a 12.23% increase from fiscal 2022.
- Edwards Lifesciences Corporation revenue from contract with customer, excluding assessed tax for fiscal 2022 was $4.46B, a 14.69% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.74B 10-Q · filed 2026-08-04 | $3.39B 10-Q · filed 2026-08-04 | $4.96B derived: sum of 3 quarters · filed 2026-08-04 | $6.51B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.65B 10-Q · filed 2026-05-06 | $3.22B derived: sum of 2 quarters · filed 2026-05-06 | $4.77B derived: sum of 3 quarters · filed 2026-05-06 | $6.30B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $1.57B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.12B derived: sum of 2 quarters · filed 2026-02-25 | $4.65B derived: sum of 3 quarters · filed 2026-08-04 | $6.07B 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $1.55B 10-Q · filed 2025-11-05 | $3.09B derived: sum of 2 quarters · filed 2026-08-04 | $4.50B 10-Q · filed 2025-11-05 | $5.88B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $1.53B 10-Q · filed 2026-08-04 | $2.94B 10-Q · filed 2026-08-04 | $4.33B derived: sum of 3 quarters · filed 2026-08-04 | $5.69B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $1.41B 10-Q · filed 2026-05-06 | $2.80B derived: sum of 2 quarters · filed 2026-05-06 | $4.15B derived: sum of 3 quarters · filed 2026-05-06 | $5.52B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $1.39B 10-K · filed 2025-02-28 | $2.74B derived: sum of 2 quarters · filed 2025-11-05 | $4.11B derived: sum of 3 quarters · filed 2025-11-05 | $5.44B 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $1.35B 10-Q · filed 2025-11-05 | $2.72B derived: sum of 2 quarters · filed 2025-11-05 | $4.05B 10-Q · filed 2025-11-05 | $5.32B derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $1.37B 10-Q · filed 2025-08-06 | $1.39B 10-Q · filed 2024-07-31 | $2.70B 10-Q · filed 2025-08-06 | $2.73B 10-Q · filed 2024-07-31 | $3.97B derived: sum of 3 quarters · filed 2025-08-06 | $5.21B derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $1.33B 10-Q · filed 2025-05-06 | $1.60B 10-Q · filed 2024-04-29 | $2.60B derived: sum of 2 quarters · filed 2025-05-06 | $3.84B derived: sum of 3 quarters · filed 2025-05-06 | $5.12B derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $1.27B 10-K · filed 2025-02-28 | $2.51B derived: sum of 2 quarters · filed 2025-02-28 | $3.79B derived: sum of 3 quarters · filed 2025-02-28 | $5.01B 10-K · filed 2026-02-25 | $6.00B 10-K · filed 2024-02-12 | |||
| 2023-09-30 | $1.24B 10-K · filed 2025-02-28 | $1.48B 10-Q · filed 2023-10-27 | $2.52B derived: sum of 2 quarters · filed 2025-02-28 | $3.74B 10-Q · filed 2024-11-06 | $4.47B 10-Q · filed 2023-10-27 | $4.17B derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $1.28B 10-K · filed 2025-02-28 | $1.53B 10-Q · filed 2023-07-28 | $2.53B 10-Q · filed 2024-07-31 | $2.99B 10-Q · filed 2023-07-28 | $2.93B derived: sum of 3 quarters · filed 2025-02-28 | $4.25B derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $1.22B 10-K · filed 2025-02-28 | $1.46B 10-Q · filed 2023-04-28 | $1.65B derived: sum of 2 quarters · filed 2025-02-28 | $2.97B derived: sum of 3 quarters · filed 2025-02-28 | $4.34B derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | $429.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.75B derived: sum of 2 quarters · filed 2025-02-28 | $3.12B derived: sum of 3 quarters · filed 2025-02-28 | $4.46B 10-K · filed 2025-02-28 | $5.38B 10-K · filed 2023-02-13 | |||
| 2022-09-30 | $1.32B 10-Q · filed 2023-10-27 | $2.69B derived: sum of 2 quarters · filed 2023-10-27 | $4.03B 10-Q · filed 2023-10-27 | $5.36B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-06-30 | $1.37B 10-Q · filed 2023-07-28 | $2.72B 10-Q · filed 2023-07-28 | $4.04B derived: sum of 3 quarters · filed 2024-02-12 | $5.36B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-03-31 | $1.34B 10-Q · filed 2023-04-28 | $2.67B derived: sum of 2 quarters · filed 2024-02-12 | $3.98B derived: sum of 3 quarters · filed 2024-02-12 | $5.36B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2021-12-31 | $1.33B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-12 | $2.64B derived: sum of 2 quarters · filed 2024-02-12 | $4.02B derived: sum of 3 quarters · filed 2024-02-12 | $5.23B 10-K · filed 2024-02-12 | ||||
| 2021-09-30 | $1.31B 10-Q · filed 2022-10-28 | $2.69B derived: sum of 2 quarters · filed 2022-10-28 | $3.90B 10-Q · filed 2022-10-28 | $5.09B derived: sum of 4 quarters · filed 2022-10-28 | ||||
| 2021-06-30 | $1.38B 10-Q · filed 2022-07-29 | $2.59B 10-Q · filed 2022-07-29 | $3.78B derived: sum of 3 quarters · filed 2022-07-29 | $4.93B derived: sum of 4 quarters · filed 2022-07-29 | ||||
| 2021-03-31 | $1.22B 10-Q · filed 2022-04-28 | $2.41B derived: sum of 2 quarters · filed 2022-04-28 | $3.55B derived: sum of 3 quarters · filed 2022-04-28 | $4.47B derived: sum of 4 quarters · filed 2022-04-28 | ||||
| 2020-12-31 | $1.19B 10-K · filed 2021-02-12 | $2.33B derived: sum of 2 quarters · filed 2021-10-29 | $3.26B derived: sum of 3 quarters · filed 2021-10-29 | $4.39B 10-K · filed 2023-02-13 | ||||
| 2020-09-30 | $1.14B 10-Q · filed 2021-10-29 | $2.07B derived: sum of 2 quarters · filed 2021-10-29 | $3.19B 10-Q · filed 2021-10-29 | $4.37B derived: sum of 4 quarters · filed 2021-10-29 | ||||
| 2020-06-30 | $925.00M 10-Q · filed 2021-07-30 | $2.05B 10-Q · filed 2021-07-30 | $3.23B derived: sum of 3 quarters · filed 2021-07-30 | $4.32B derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $1.13B 10-Q · filed 2021-04-28 | $2.30B derived: sum of 2 quarters · filed 2021-04-28 | $3.40B derived: sum of 3 quarters · filed 2021-04-28 | $4.48B derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | $1.17B 10-K · filed 2021-02-12 | $2.27B derived: sum of 2 quarters · filed 2021-02-12 | $3.35B derived: sum of 3 quarters · filed 2021-02-12 | $4.35B 10-K · filed 2022-02-14 | ||||
| 2019-09-30 | $1.09B 10-K · filed 2021-02-12 | $2.18B derived: sum of 2 quarters · filed 2021-02-12 | $3.17B 10-Q · filed 2020-10-26 | $4.15B derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | $1.09B 10-K · filed 2021-02-12 | $2.08B 10-Q · filed 2020-07-27 | $3.06B derived: sum of 3 quarters · filed 2021-02-12 | $3.96B derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $993.00M 10-K · filed 2021-02-12 | $1.97B derived: sum of 2 quarters · filed 2021-02-12 | $2.88B derived: sum of 3 quarters · filed 2021-02-12 | $3.82B derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $977.70M 10-K · filed 2020-02-14 | $1.88B derived: sum of 2 quarters · filed 2020-02-14 | $2.83B derived: sum of 3 quarters · filed 2020-02-14 | $3.72B 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | $906.60M 10-K · filed 2020-02-14 | $1.85B derived: sum of 2 quarters · filed 2020-02-14 | $2.75B 10-Q · filed 2019-10-25 | $3.63B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | $943.70M 10-K · filed 2020-02-14 | $1.84B 10-Q · filed 2019-07-26 | $2.73B derived: sum of 3 quarters · filed 2020-02-14 | $3.55B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | $894.80M 10-K · filed 2020-02-14 | $1.78B derived: sum of 2 quarters · filed 2020-02-14 | $2.60B derived: sum of 3 quarters · filed 2020-02-14 | $3.45B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2017-12-31 | $888.50M 10-K · filed 2019-02-15 | $1.71B derived: sum of 2 quarters · filed 2019-02-15 | $2.55B derived: sum of 3 quarters · filed 2019-02-15 | $3.44B 10-K · filed 2020-02-14 | ||||
| 2017-09-30 | $821.50M 10-K · filed 2019-02-15 | $1.66B derived: sum of 2 quarters · filed 2019-02-15 | $2.55B 10-Q · filed 2018-10-26 | |||||
| 2017-06-30 | $841.80M 10-K · filed 2019-02-15 | $1.73B 10-Q · filed 2018-07-27 | ||||||
| 2017-03-31 | $883.50M 10-K · filed 2019-02-15 | |||||||
| 2016-12-31 | $2.96B 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |